362 related articles for article (PubMed ID: 33487481)
21. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective.
Bridoux F; Javaugue V; Nasr SH; Leung N
Nephrol Dial Transplant; 2021 Jan; 36(2):208-215. PubMed ID: 33494099
[TBL] [Abstract][Full Text] [Related]
22. A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.
Lerner GB; Virmani S; Henderson JM; Francis JM; Beck LH
Kidney Int; 2021 Aug; 100(2):289-300. PubMed ID: 33857571
[TBL] [Abstract][Full Text] [Related]
23. Perspectives in membranous nephropathy.
Tomas NM; Huber TB; Hoxha E
Cell Tissue Res; 2021 Aug; 385(2):405-422. PubMed ID: 33825066
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis.
Dai P; Xie W; Yu X; Sun J; Wang S; Kawuki J
Int Immunopharmacol; 2021 May; 94():107376. PubMed ID: 33582591
[TBL] [Abstract][Full Text] [Related]
25. Protocadherin 7-Associated Membranous Nephropathy.
Sethi S; Madden B; Debiec H; Morelle J; Charlesworth MC; Gross L; Negron V; Buob D; Chaudhry S; Jadoul M; Fervenza FC; Ronco P
J Am Soc Nephrol; 2021 May; 32(5):1249-1261. PubMed ID: 33833079
[TBL] [Abstract][Full Text] [Related]
26. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Floege J; Rovin BH
Kidney Int; 2021 Apr; 99(4):811-813. PubMed ID: 33745547
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens.
Ramachandran R; Nayak S; Kumar V; Sethi J; Minz R; Kumar V; Rathi M; Kohli HS
Nephrol Dial Transplant; 2021 Feb; ():. PubMed ID: 33576822
[No Abstract] [Full Text] [Related]
28. Membranous nephropathy.
Ronco P; Beck L; Debiec H; Fervenza FC; Hou FF; Jha V; Sethi S; Tong A; Vivarelli M; Wetzels J
Nat Rev Dis Primers; 2021 Sep; 7(1):69. PubMed ID: 34593809
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study.
Lanaret C; Anglicheau D; Audard V; Büchler M; Caillard S; Couzi L; Malvezzi P; Mesnard L; Bertrand D; Martinez F; Pernin V; Ducloux D; Poulain C; Thierry A; Del Bello A; Rerolle JP; Greze C; Uro-Coste C; Aniort J; Lambert C; Bouvier N; Schvartz B; Maillard N; Sayegh J; Oniszczuk J; Morin MP; Legendre C; Kamar N; Heng AE; Garrouste C
Am J Transplant; 2021 Sep; 21(9):3021-3033. PubMed ID: 33512779
[TBL] [Abstract][Full Text] [Related]
30. Membranous Nephropathy: From Research Bench to Personalized Care.
Moszczuk B; Kiryluk K; Pączek L; Mucha K
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799372
[TBL] [Abstract][Full Text] [Related]
31. Membranous Nephropathy: Classification Redux?
Glassock RJ
Mayo Clin Proc; 2021 Mar; 96(3):523-525. PubMed ID: 33673902
[No Abstract] [Full Text] [Related]
32. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R
J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907
[TBL] [Abstract][Full Text] [Related]
33. Neural Epidermal Growth Factor-Like 1 Protein-Positive Membranous Nephropathy in Chinese Patients.
Wang G; Sun L; Dong H; Wang Y; Xu X; Zhao Z; Cheng W; Liu X; Zhao X; Geng Y; Bao S; Chen Y; Cheng H
Clin J Am Soc Nephrol; 2021 May; 16(5):727-735. PubMed ID: 33849930
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiology, diagnosis, and treatment of membranous nephropathy.
Lutz J
Nephrol Ther; 2021 Apr; 17S():S1-S10. PubMed ID: 33910688
[TBL] [Abstract][Full Text] [Related]
35. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy.
Motavalli R; Etemadi J; Soltani-Zangbar MS; Ardalan MR; Kahroba H; Roshangar L; Nouri M; Aghebati-Maleki L; Khiavi FM; Abediazar S; Mehdizadeh A; Hojjat-Farsangi M; Mahmoodpoor A; Kafil HS; Zolfaghari M; Ahmadian Heris J; Yousefi M
Cytokine; 2021 May; 141():155452. PubMed ID: 33571932
[TBL] [Abstract][Full Text] [Related]
36. Management of Heart Failure Patient with CKD.
Banerjee D; Rosano G; Herzog CA
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1131-1139. PubMed ID: 33495289
[TBL] [Abstract][Full Text] [Related]
37. Emerging B-Cell Therapies in Systemic Lupus Erythematosus.
Bag-Ozbek A; Hui-Yuen JS
Ther Clin Risk Manag; 2021; 17():39-54. PubMed ID: 33488082
[TBL] [Abstract][Full Text] [Related]
38. Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.
Al-Rabadi LF; Caza T; Trivin-Avillach C; Rodan AR; Andeen N; Hayashi N; Williams B; Revelo MP; Clayton F; Abraham J; Lin E; Liou W; Zou CJ; Ramkumar N; Cummins T; Wilkey DW; Kawalit I; Herzog C; Storey A; Edmondson R; Sjoberg R; Yang T; Chien J; Merchant M; Arthur J; Klein J; Larsen C; Beck LH
J Am Soc Nephrol; 2021 Jul; 32(7):1666-1681. PubMed ID: 33952630
[TBL] [Abstract][Full Text] [Related]
39. Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Delafosse M; Ponlot E; Esteve E; Ghislain L; Hanset N; Boffa JJ; Johanet C; Dahan K
Kidney Int; 2021 Apr; 99(4):1023-1024. PubMed ID: 33745532
[No Abstract] [Full Text] [Related]
40. Primary membranous nephropathy in the era of autoantibodies and biological therapies.
Rojas-Rivera JE; Ortiz Arduán A
Med Clin (Barc); 2021 Aug; 157(3):121-129. PubMed ID: 33832765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
